UY26696A1 - Método para regular la angiogénesis utilizando proteína ryk - Google Patents

Método para regular la angiogénesis utilizando proteína ryk

Info

Publication number
UY26696A1
UY26696A1 UY26696A UY26696A UY26696A1 UY 26696 A1 UY26696 A1 UY 26696A1 UY 26696 A UY26696 A UY 26696A UY 26696 A UY26696 A UY 26696A UY 26696 A1 UY26696 A1 UY 26696A1
Authority
UY
Uruguay
Prior art keywords
ryk
anglogenesis
proteins
diseases
protein
Prior art date
Application number
UY26696A
Other languages
English (en)
Spanish (es)
Inventor
Steve Roczniak
Nathalie A Dubois-Stringfellow
Alya Zolotorev
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of UY26696A1 publication Critical patent/UY26696A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
UY26696A 2000-05-10 2001-05-08 Método para regular la angiogénesis utilizando proteína ryk UY26696A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56878300A 2000-05-10 2000-05-10

Publications (1)

Publication Number Publication Date
UY26696A1 true UY26696A1 (es) 2001-12-28

Family

ID=24272718

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26696A UY26696A1 (es) 2000-05-10 2001-05-08 Método para regular la angiogénesis utilizando proteína ryk

Country Status (13)

Country Link
EP (1) EP1287121A2 (enExample)
JP (1) JP2004527206A (enExample)
AR (1) AR028424A1 (enExample)
AU (1) AU2001261343A1 (enExample)
CA (1) CA2408349A1 (enExample)
CO (1) CO5300464A1 (enExample)
DO (1) DOP2001000164A (enExample)
EC (1) ECSP014068A (enExample)
GT (1) GT200100079A (enExample)
PE (1) PE20011218A1 (enExample)
SV (1) SV2002000442A (enExample)
UY (1) UY26696A1 (enExample)
WO (1) WO2001085789A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1471934A2 (en) * 2002-02-06 2004-11-03 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Kinases involved in the regulation of energy homeostasis
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
WO2016008975A1 (en) 2014-07-18 2016-01-21 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
TW202315894A (zh) * 2021-08-18 2023-04-16 美國加利福尼亞大學董事會 抗受體相關酪胺酸激酶(ryk)抗體及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023429A1 (en) * 1992-05-11 1993-11-25 Ludwig Institute For Cancer Research Receptor-type tyrosine kinase-like molecules
KR19980701950A (ko) * 1994-12-23 1998-06-25 에드워드 에이. 맥더모 2세, 로이드 제이. 오울드 분석, 리셉터 단백질 및 리간드
AU4278299A (en) * 1998-06-11 1999-12-30 Astrazeneca Ab Human receptor tyrosine kinase
WO2000024415A2 (en) * 1998-10-28 2000-05-04 Cornell Research Foundation, Inc. Methods for regulating angiogenesis and vascular integrity using trk receptor ligands

Also Published As

Publication number Publication date
GT200100079A (es) 2001-12-31
ECSP014068A (es) 2002-02-25
AU2001261343A1 (en) 2001-11-20
PE20011218A1 (es) 2002-02-01
WO2001085789A3 (en) 2002-05-16
CO5300464A1 (es) 2003-07-31
DOP2001000164A (es) 2002-05-15
CA2408349A1 (en) 2001-11-15
SV2002000442A (es) 2002-07-03
WO2001085789A2 (en) 2001-11-15
JP2004527206A (ja) 2004-09-09
AR028424A1 (es) 2003-05-07
EP1287121A2 (en) 2003-03-05

Similar Documents

Publication Publication Date Title
UY28396A1 (es) Trompas de vegf y usos terapéuticos de las mismas
CY1119951T1 (el) Συνθεσεις για αυξηση δραστηριοτητας τελομερασης και αγωγη λοιμωξης hiv
TR200101307T2 (tr) Antranilik asit amidler ve ilaç olarak kullanılmaları.
CY1107248T1 (el) Συντηγμενες πρωτεϊνες
ECSP034548A (es) Derivados de quinolinona como inhibidores de tirosin quinasa
EA200400482A1 (ru) Кератиноциты, пригодные для применения в качестве биологически активной субстанции при лечении ран
AR039511A1 (es) Agentes que regulan, inhiben, o modulan la actividad y/o la expresion del factor de crecimiento del tejido conjuntivo (ctgf) como unico medio para disminuir la presion intraocular y para tratar las retinopatias glaucomatosas/neuropatias opticas
ES2080837T3 (es) Tratamiento de estados y enfermedades.
SV1995000007A (es) Derivados del acido micofenolico 5-substituidos.
Philp et al. Thymosin beta 4 induces hair growth via stem cell migration and differentiation
Tak et al. Oral submucous fibrosis: A review article on etiopathogenesis
UY26696A1 (es) Método para regular la angiogénesis utilizando proteína ryk
DK1343472T3 (da) Thixotropisk næsespray
ES2162331T3 (es) Utilizacion del factor de crecimiento del tejido nervioso para conservacion, cultivo o tratamiento de la cornea.
AR030345A1 (es) Metodo de tratamiento de desordenes relacionados con angiogenesis
ATE556134T1 (de) Mesenchymstammzellen und verwendungendafür
ATE390937T1 (de) Methoden zur behandlung von hyperproliferativen krankheiten mit menschlichem mda-7
EP1050309A4 (en) NEUROTROPHIC FACTOR SECRETION PROMOTERS
ATE283058T1 (de) Verwendung einer pollenextrakt-hältigen verbindung zur behandlung von dysphorie
UY26649A1 (es) Proteína que tiene actividad moduladora de angiogenesis
ATE374048T1 (de) Verwendung von matrixprotein für gesteuerte geweberegenerationen
Sajjad et al. The The Therapeutic Effects of Autologous Platelet-Rich Plasma Gel on Cutaneous Wound Healing in Rescued Horses: The Effects of Autologous Platelet-Rich Plasma Gel on skin Wound Healing in Horses
ATE302000T1 (de) Pharmazeutische zusammensetzung enthaltend famotidine für die behandlung von depressionen
Weiss et al. Molecules in focus Endothelial cell stimulating angiogenesis factor
US20230038408A1 (en) Biophotonic compositions, uses and methods for modulating mitochondrial dynamics and functionality in skin and soft tissue conditions

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20131119